Researchers Discover Melanoma Drug Target That Occurs In Prostate Cancer
Posted Jun 16 2010 6:49pm
Anti-RAF drugs already in clinical trials for melanoma; could be evaluated in lethal RAF-driven prostate cancers
Researchers at the University of Michigan Comprehensive Cancer Center have discovered the RAF oncogene that drives fatal melanomas may also drive the aggressive forms of prostate cancer in the clinic.
The DNA rearrangement in prostate cancer cells, caused by chromosomal fusions of RAF, appears to be diagnostic, and permit the rapid creation of clinical trials that include both melanoma and prostate cancer patients in the same trial to receive anti-RAF drugs. Melanomas and prostate cancers are not usually associated with each other in treatment approaches.
The finding is reported online ahead of print publication in Nature Medicine.